The Clinical Significance of<i>Ureaplasma urealyticum</i>in Chronic prostatitis

Radonić, Ana; Kovačević, Višnja; Markotić, Alemka; Škerk, Vedrana; Turčić, Petra; Škerk, Višnja

doi:10.1179/joc.2009.21.4.465

Cited by 11 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To verify the reliability of the method, all the standard strains available (serovar [1][2][3][4][5][6][7][8][9][10][11][12][13][14] were assayed with both the biovar specific primers and probes, the positive and negative controls were set in the experiments. In addition, 1.0×10 1-8 copies/ml U urealyticum nucleic acid was detected to determine the linear range and sensitivity.…”

Section: Deoxyribonucleic Acid Extractionmentioning

confidence: 99%

Investigation of Ureaplasma urealyticum biovars and their relationship with antimicrobial resistance

Zhu

Dong

et al. 2011

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

(1) Our new established Taqman PCR method is a useful tool for screening UU biovars. (2) UU biovar 1 predominated in asymptomatic population; whereas in genital-urinary tract infection population UU biovar 2 had a higher proportion. (3) The characteristics of drug resistance were different between UU biovars. Overall, both two biovars remained higher susceptibility rates to tetracyclines. A majority of biovor 1 strains were sensitive to macrolides and quinolones; while only a small number of biovar 2 strains kept sensitive to roxithromycin and quinolones, a large proportion of biovar 2 strains were found in intermediate ranges.

show abstract

Section: Deoxyribonucleic Acid Extractionmentioning

confidence: 99%

Investigation of Ureaplasma urealyticum biovars and their relationship with antimicrobial resistance

Zhu

Dong

et al. 2011

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…К этиопатогенетическим факторам снижения мужской фертильности эксперты Европейской ассоциации урологов (European Association of Uro logy) относят: аномалии мочеполовых органов, злокачественные опухоли, инфекции мочеполовой системы, варикоцеле, генетические и иммунологические нарушения [5]. Эксперты ВОЗ считают факторами риска нарушения мужской фертильности воспалительные заболевания добавочных половых желез (простатиты, эпидидимиты), обусловленные инфекциями, передаваемыми половым путем (ИППП), которые влияют на секреторную функцию добавочных половых желез, снижают выработку лимонной кислоты, фосфотазы, цинка, фруктозы и приводят к секреторному, экскреторному, иммунному мужскому бесплодию, нарушению гематотестикулярного барьера и выработке антиспермальных антител (АСА), что требует длительного лечения, иногда с использованием вспомогательных репродуктивных технологий (ВРТ) [12][13][14]. Микроорганизмы при заболеваниях, передаваемых половым путем, выходят в клеточное пространство, достигают тазовых, преаортальных лимфатических узлов, контактируют с лимфоцитами периферической крови, адсорбируются на мембранах клеток эпителия, сперматозоидах, проникают в секрет предстательной железы (ПЖ), повышают уровень АСА в эякуляте, сыворотке крови, ухудшая сперматологические, репродуктивные показатели, но эти нарушения при лечении потенциально устранимы.…”

Section: Introductionunclassified

Prospects of systemic enzyme therapy for treatment of male immune infertility

Kalinina

Кореньков

Fesenko

et al. 2020

Androl. genit. hir.

View full text Add to dashboard Cite

The study objective is to evaluate the effectiveness and safety of systemic enzyme therapy drugs (Wobenzym, Phlogenzym) and the natural complex of multi-component dietary supplement Spermstrong in the treatment of immune infertility.Materials and methods. Sixty-four men with immune infertility, high levels of antisperm antibodies (ASA) in ejaculate, serum and reproductive disorders were examined. All patients were divided into 2 groups. For 8 weeks, 32 patients in the group 1 received systemic enzyme therapy drugs in combination with a natural complex of multi-component dietary supplement Spermstrong (combined therapy), and 32 patients of the group 2 received only Spermstrong (monotherapy), and their comparative assessment was carried out. Immediate results of treatment were evaluated 4 weeks later and remote 8 weeks after treatment.Results. Increased ejaculate volume was observed in patients receiving combination therapy and Spermstrong only: by 19.0 and 10.0 %, respectively, after 4 weeks of treatment and by 42.9 and 15.0 % after 8 weeks. Mean sperm count increased only in patients receiving combination therapy (by 55.4 % after 8 weeks of treatment, p <0.05). Sperm motility increased more after combination therapy (by 11.9 and 129.8 % after 4 and 8 weeks, respectively). Decrease in abnormal spermatozoa was slightly faster for combination treatment compared to Spermstrong monotherapy: after 4 weeks by 12.2 and 0.3 %, respectively, after 8 weeks by 24.8 and 6.5 %. The level of ASA IgG in the ejaculate decreased by 26.3 and 59.0 % after 4 and 8 weeks of combination treatment, and by 3.4 and 13.2 % after Spermstrong monotherapy. Serum level of ASA IgG/IgM significantly decreased only in patients receiving combination therapy (by 36.4 and 76.5 % after 4 and 8 weeks, respectively, p <0.05). No adverse effects were observed in patients in both treatment groups.Conclusion. The results confirm that the use of combination therapy with Wobenzym, Phlogenzym and Spermstrong statistically significantly reduced ASA levels and increased the effectiveness of treatment.The authors declare no conflict of interest.All patients gave written informed consent to participate in the study.

show abstract

“…Увеличивается частота хламидийной инфекции в сочетании с мико-плазменной, трихомонадной, герпетической, гонокок-ковой, папилломавирусной ИППП. Без свое временной диагностики и лечения ЗППП у супружеской пары мо-гут возникнуть осложнения в виде бесплодия [7][8][9][10][11][12].…”

Section: Introductionunclassified